BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
Portfolio Pulse from
BridgeBio Pharma reported its Q4 and full-year 2024 financial results, highlighting the success of its drug Attruby™ (acoramidis) for ATTR-CM, with significant prescriptions and FDA and EU approvals. The company also completed enrollment for three global studies and ended the quarter with $681 million in cash.
February 20, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BridgeBio Pharma's Attruby™ (acoramidis) has shown strong market uptake with over 1,000 prescriptions since FDA approval. The EU approval as BEYONTTRA™ brings a $75M milestone and ongoing royalties. The company is financially strong with $681M in cash.
The successful launch and approval of Attruby™ in both the US and EU markets, along with significant milestone payments and royalties, indicate strong revenue potential. The company's robust cash position further supports its financial health, likely boosting investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100